Skip to main content
KLDOOTCinactive

Kaleido Biosciences, Inc.

Biopharma developer (SEC filing verified)·Phase 2·Lexington, MA, United States·CEO: Daniel L Menichella
ImmunologyInfectious Disease

KLDO evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for KLDO—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

3.5/10

BioSniper Score

Based on 4 of 6 signals

Market Cap

$4K

Cash Runway

7.2 mo

Lead Asset

kb109 (Preclinical)

Next Catalyst

Financial data as of Dec 31, 2021.

Tracking 3 pipeline candidates for Kaleido Biosciences, Inc..

Run Kaleido Biosciences, Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Kaleido Biosciences, Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 4 of 6 signals · derived from public data

Cash Runway2.0

7.2 months

Financial Health0.0

D/E 3.73

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Pipeline

Financials

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

2

Total value held

$0

Short Interest

as of May 21, 2026
% of float
14.2%
Days to cover
29.3
Shares short
2,339,422
Daily short volume
-

Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →

KLDO short interest

Frequently asked questions

What is Kaleido Biosciences, Inc.'s lead drug candidate?

Kaleido Biosciences, Inc.'s most advanced tracked candidate is kb109 (Preclinical) for Mild to moderate COVID-19.

Who is the CEO of Kaleido Biosciences, Inc.?

Daniel L Menichella is the chief executive officer of Kaleido Biosciences, Inc. (KLDO).

Where is Kaleido Biosciences, Inc. headquartered?

Kaleido Biosciences, Inc. (KLDO) is headquartered in Lexington, MA, United States.

What therapeutic areas does Kaleido Biosciences, Inc. focus on?

Kaleido Biosciences, Inc. develops therapies across Immunology, Infectious Disease.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.